BR112017009440A2 - uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) - Google Patents
uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)Info
- Publication number
- BR112017009440A2 BR112017009440A2 BR112017009440A BR112017009440A BR112017009440A2 BR 112017009440 A2 BR112017009440 A2 BR 112017009440A2 BR 112017009440 A BR112017009440 A BR 112017009440A BR 112017009440 A BR112017009440 A BR 112017009440A BR 112017009440 A2 BR112017009440 A2 BR 112017009440A2
- Authority
- BR
- Brazil
- Prior art keywords
- host disease
- versus host
- graft versus
- inhibitor
- gvhd
- Prior art date
Links
- 108010077544 Chromatin Proteins 0.000 title 1
- 208000009329 Graft vs Host Disease Diseases 0.000 title 1
- 210000003483 chromatin Anatomy 0.000 title 1
- 208000024908 graft versus host disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 101150090105 Ezh2 gene Proteins 0.000 abstract 2
- 208000017760 chronic graft versus host disease Diseases 0.000 abstract 2
- 229940121649 protein inhibitor Drugs 0.000 abstract 2
- 239000012268 protein inhibitor Substances 0.000 abstract 2
- UMZWNADQRDCKII-UHFFFAOYSA-N 2-[5-(5-bromo-2-oxoindol-3-yl)-4-hydroxy-2-sulfanylidene-1,3-thiazol-3-yl]butanedioic acid Chemical compound OC(=O)CC(C(O)=O)n1c(O)c(sc1=S)C1=c2cc(Br)ccc2=NC1=O UMZWNADQRDCKII-UHFFFAOYSA-N 0.000 abstract 1
- 229940096923 Bcl6 inhibitor Drugs 0.000 abstract 1
- 102000001805 Bromodomains Human genes 0.000 abstract 1
- 108050009021 Bromodomains Proteins 0.000 abstract 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 abstract 1
- 102000013538 Proto-Oncogene Proteins c-bcl-6 Human genes 0.000 abstract 1
- 108010090920 Proto-Oncogene Proteins c-bcl-6 Proteins 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076358P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/059551 WO2016073903A1 (en) | 2014-11-06 | 2015-11-06 | Use of compositions modulating chromatin structure for graft versus host disease (gvhd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017009440A2 true BR112017009440A2 (pt) | 2017-12-19 |
Family
ID=55909890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017009440A BR112017009440A2 (pt) | 2014-11-06 | 2015-11-06 | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190000860A1 (https=) |
| EP (1) | EP3215160A4 (https=) |
| JP (1) | JP2017533922A (https=) |
| KR (1) | KR20170098808A (https=) |
| CN (1) | CN107249593A (https=) |
| AU (1) | AU2015342895A1 (https=) |
| BR (1) | BR112017009440A2 (https=) |
| CA (1) | CA2966336A1 (https=) |
| WO (1) | WO2016073903A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL285201B2 (en) | 2014-06-17 | 2024-05-01 | Epizyme Inc | EZH2 inhibitors for the treatment of lymphoma |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| JP7493304B2 (ja) | 2016-04-22 | 2024-05-31 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｅｚｈ２インヒビターおよびそれらの使用 |
| TW201831181A (zh) | 2017-01-19 | 2018-09-01 | 日商第一三共股份有限公司 | 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| MX2020007974A (es) | 2018-01-31 | 2020-09-07 | Mirati Therapeutics Inc | Inhibidores de complejo represivo polycomb 2 (prc2). |
| CN108685880A (zh) * | 2018-04-16 | 2018-10-23 | 广东省人民医院(广东省医学科学院) | Bcl-6小分子抑制剂用于制备预防或治疗cGVHD的药物 |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| US20220016111A1 (en) * | 2018-12-21 | 2022-01-20 | The Walter And Eliza Hall Institute Of Medical Research | Methods of Treating Inflammation |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| CN112341390B (zh) * | 2019-08-07 | 2022-08-23 | 四川大学 | 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| EP4514391A1 (en) | 2022-04-27 | 2025-03-05 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
| JP2025526656A (ja) * | 2022-08-09 | 2025-08-15 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | 大環状ｂｃｌ６分解剤 |
| WO2024211684A1 (en) * | 2023-04-06 | 2024-10-10 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2250154T3 (es) * | 1999-07-16 | 2006-04-16 | Kissei Pharmaceutical Co., Ltd. | Agentes que inhiben las reacciones de rechazo cronico despues de un transplante de organo. |
| WO2008066887A2 (en) * | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| KR20080107050A (ko) * | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| US20120014979A1 (en) * | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| CN104039956A (zh) * | 2011-11-04 | 2014-09-10 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 治疗方法 |
| WO2013123521A1 (en) * | 2012-02-17 | 2013-08-22 | Nexbio, Inc. | Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients |
| WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
-
2015
- 2015-11-06 US US15/524,707 patent/US20190000860A1/en not_active Abandoned
- 2015-11-06 EP EP15856340.3A patent/EP3215160A4/en not_active Withdrawn
- 2015-11-06 JP JP2017525115A patent/JP2017533922A/ja active Pending
- 2015-11-06 AU AU2015342895A patent/AU2015342895A1/en not_active Abandoned
- 2015-11-06 CN CN201580066388.8A patent/CN107249593A/zh active Pending
- 2015-11-06 KR KR1020177014969A patent/KR20170098808A/ko not_active Withdrawn
- 2015-11-06 BR BR112017009440A patent/BR112017009440A2/pt not_active Application Discontinuation
- 2015-11-06 CA CA2966336A patent/CA2966336A1/en not_active Abandoned
- 2015-11-06 WO PCT/US2015/059551 patent/WO2016073903A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017533922A (ja) | 2017-11-16 |
| EP3215160A4 (en) | 2018-08-08 |
| KR20170098808A (ko) | 2017-08-30 |
| US20190000860A1 (en) | 2019-01-03 |
| EP3215160A1 (en) | 2017-09-13 |
| AU2015342895A1 (en) | 2017-05-18 |
| WO2016073903A1 (en) | 2016-05-12 |
| CA2966336A1 (en) | 2016-05-12 |
| CN107249593A (zh) | 2017-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
| DOP2020000252A (es) | Inhibidores de proteina tirosina fosfatasa y sus métodos de uso | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
| BR112016028066A2 (pt) | composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira | |
| MX2018003824A (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control. | |
| BR112018008918A8 (pt) | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| CR20170219A (es) | Inhibidores del bromodominio | |
| MX2020012064A (es) | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| AU2016304856A8 (en) | Mechanism of resistance to BET bromodomain inhibitors | |
| BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112018012177A2 (pt) | ?moduladores de hidantação de canais kv 3? | |
| BR112018002427A2 (pt) | terapias de combinação para tratamento do câncer | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| BR112019000635A2 (pt) | inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| BR112022001985A2 (pt) | Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina | |
| MX394015B (es) | Inhibición de la actividad de la olig2. | |
| AR117094A1 (es) | Moduladores de expresión irf5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |